BridgeMD
Prevention study for Heart Failure Acute
Official title Contrast-Induced Acute Kidney Injury Prevention in Acute Heart Failure
ClinicalTrials.gov ID: NCT07550790
What this study is testing
What is Furosemide?
Furosemide is an investigational medicine, given as an once-daily infusion into a vein, being studied as a potential treatment for heart failure acute.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The K-PROSE study is a randomized clinical investigation evaluating strategies to prevent contrast-induced acute kidney injury (CI-AKI) in patients hospitalized with acute heart failure and moderate renal dysfunction (eGFR 30-75 mL/min/1.73 m²). Patients requiring contrast-enhanced CT imaging are randomized to either standard intravenous saline hydration or a furosemide-based decongestion strategy.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 and older
You may be able to join if
- Adults aged 20 years or older
- Emergency department visit/hospitalization for acute heart failure with clinical evidence of congestion
- Planned contrast-enhanced computed tomography during the index hospitalization
- Baseline renal dysfunction defined as an estimated glomerular filtration rate (eGFR) of 30-75 mL/min/1.73 m²
You likely can't join if
- Requirement for vasopressor therapy
- Requirement for renal replacement therapy (dialysis)
- Known allergy or hypersensitivity to furosemide
- Ongoing acute coronary syndrome
- Pregnant or breastfeeding women, or women of childbearing potential without a negative pregnancy test
- Hyperkalemia (serum potassium \>5.5 mmol/L)
See the full eligibility criteria
- Adults aged 20 years or older
- Emergency department visit/hospitalization for acute heart failure with clinical evidence of congestion
- Planned contrast-enhanced computed tomography during the index hospitalization
- Baseline renal dysfunction defined as an estimated glomerular filtration rate (eGFR) of 30-75 mL/min/1.73 m²
- Requirement for vasopressor therapy
- Requirement for renal replacement therapy (dialysis)
- Known allergy or hypersensitivity to furosemide
- Ongoing acute coronary syndrome
- Pregnant or breastfeeding women, or women of childbearing potential without a negative pregnancy test
- Hyperkalemia (serum potassium \>5.5 mmol/L)
- Uncorrected volume depletion or hyponatremia (serum sodium \<130 mmol/L)
- Any condition deemed by the investigator to make participation in the study inappropriate
The study team makes the final eligibility decision.
Where it's taking place
- Seongnam-si, Gyeonggi-do, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Seongnam-si, Gyeonggi-do, South Korea. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.